Alexander Y. Walley, MD

Associate Professor, Medicine

Alexander Walley
801 Massachusetts Ave Crosstown Center

Biography

Dr Walley is Associate Professor of Medicine and an addiction expert at Boston Medical Center and Boston University School of Medicine. Dr Walley has conducted multiple studies related to the opioid crisis and the integration of addiction specialty care and general medical care. He has served as PI on a CDC-SAMHSA-Epi-AID investigation of the surge in fentanyl-related overdose, a CDC-funded study of the Massachusetts OEND program which demonstrated community-level reductions in overdose death rates, and a SAMHSA-funded program that integrated addiction treatment into the clinical care of people with/at risk for HIV. He has worked as Co-I with addiction, overdose, and HIV expertise on NIDA and NIAAA-funded clinical trials and cohort studies.

Dr Walley is the director of the Boston Medical Center Addiction Medicine Fellowship program, as well as the director the NIDA-funded Fellow Immersion Training program in Addiction Medicine, which trains 5 subspecialty fellows each year to integrate addiction science into their subspecialty research. He provides primary care and addiction medicine consultations in the HIV primary care clinic at Boston University School of Medicine/BMC where he leads the FAST PATH (Facilitated Access to Substance abuse Treatment for Prevention and Treatment of HIV) program. Dr Walley co-founded and provides care on the inpatient addiction consult service at Boston Medical Center, which regularly provides consultation for patients admitted to the hospital who use alcohol and substances. Lastly, Dr Walley has been the medical director of the Massachusetts Opioid Overdose Prevention program since it started in 2007. They have trained and equipped over 80,000 people in the community with naloxone rescue kits, culminating in over 19,000 documented overdose rescues.

Other Positions

  • Member, Evans Center for Interdisciplinary Biomedical Research, Boston University
  • Faculty, Clinical Addiction Research and Education Unit, Medicine, Boston University School of Medicine
  • Courtesy Staff Privileges, Medicine, Boston Medical Center

Education

  • Johns Hopkins University School of Medicine, MD
  • Boston University School of Public Health, MSc
  • Harvard College, AB

Classes Taught

  • GMSMS710

Publications

  • Published on 8/29/2021

    Harris MT, Seliga RK, Fairbairn N, Nolan S, Walley AY, Weinstein ZM, Turnbull J. Outcomes of Ottawa, Canada's Managed Opioid Program (MOP) where supervised injectable hydromorphone was paired with assisted housing. Int J Drug Policy. 2021 Aug 29; 98:103400. PMID: 34469781.

    Read at: PubMed
  • Published on 6/1/2021

    Kimmel S, Bach P, Walley AY. Treatment of Refractory Opioid Use Disorder : Comparison of Treatment Options for Refractory Opioid Use Disorder in the United States and Canada: A Narrative Review. J Gen Intern Med. 2021 06; 36(6):1793. PMID: 33772440.

    Read at: PubMed
  • Published on 5/21/2021

    Morgan JR, Walley AY, Murphy SM, Chatterjee A, Hadland SE, Barocas J, Linas BP, Assoumou SA. Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort. Drug Alcohol Depend. 2021 Aug 01; 225:108764. PMID: 34051547.

    Read at: PubMed
  • Published on 4/30/2021

    Park TW, Sikov J, dellaBitta V, Saitz R, Walley AY, Drainoni ML. "It could potentially be dangerous... but nothing else has seemed to help me.": Patient and clinician perspectives on benzodiazepine use in opioid agonist treatment. J Subst Abuse Treat. 2021 Apr 30; 131:108455. PMID: 34098286.

    Read at: PubMed
  • Published on 4/20/2021

    Roy PJ, Price R, Choi S, Weinstein ZM, Bernstein E, Cunningham CO, Walley AY. Shorter outpatient wait-times for buprenorphine are associated with linkage to care post-hospital discharge. Drug Alcohol Depend. 2021 Jul 01; 224:108703. PMID: 33964730.

    Read at: PubMed
  • Published on 4/9/2021

    Jawa R, Rozansky H, Clemens D, Fagan M, Walley AY. Rethinking Home-based Outpatient Parenteral Antibiotic Therapy for Persons Who Inject Drugs: An Opportunity for Change in the Time of COVID-19. J Addict Med. 2021 Apr 09. PMID: 33870955.

    Read at: PubMed
  • Published on 4/1/2021

    Kerensky T, LaRochelle M, Fan SL, Kosakowski S, Wason K, Walley AY. Non-prescription Fentanyl Positive Toxicology: Prevalence, Positive Predictive Value of Fentanyl Immunoassay Screening, and Description of Co-substance Use. J Addict Med. 2021 04 01; 15(2):150-154. PMID: 32909981.

    Read at: PubMed
  • Published on 3/23/2021

    Bagley SM, Hadland SE, Schoenberger SF, Gai MJ, Topp D, Hallett E, Ashe E, Samet JH, Walley AY. Integrating substance use care into primary care for adolescents and young adults: Lessons learned. J Subst Abuse Treat. 2021 Oct; 129:108376. PMID: 34080547.

    Read at: PubMed
  • Published on 3/15/2021

    Kimmel SD, Walley AY, Lodi S, Forman LS, Liebschutz JM, Lira MC, Kim TW, Del Rio C, Samet JH, Tsui JI. Naloxone receipt and overdose prevention care among people with HIV on chronic opioid therapy. AIDS. 2021 03 15; 35(4):697-700. PMID: 33587441.

    Read at: PubMed
  • Published on 2/1/2021

    Linas BP, Savinkina A, Madushani RWMA, Wang J, Eftekhari Yazdi G, Chatterjee A, Walley AY, Morgan JR, Epstein RL, Assoumou SA, Murphy SM, Schackman BR, Chrysanthopoulou SA, White LF, Barocas JA. Projected Estimates of Opioid Mortality After Community-Level Interventions. JAMA Netw Open. 2021 02 01; 4(2):e2037259. PMID: 33587136.

    Read at: PubMed

View 148 more publications: View full profile at BUMC

View all profiles